Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wai-Kay Seto

Showing results (41-50 of 326) with videos related to

Pageof 33
Sort By:
Lancet (London, England)|November 30, 2018
Chronic hepatitis B virus infectionWai-Kay Seto, Ying-Ru Lo, Jean-Michel Pawlotsky, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 3, 2018
An update on the toxicological considerations for protease inhibitors used for hepatitis C infectionLung-Yi Mak, Wai-Kay Seto, Ching-Lung Lai, et al.
Annals of Hematology|June 28, 2018
Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatmentHarinder Gill, Garret M K Leung, Wai-Kay Seto, et al.
Expert Opinion on Emerging Drugs|May 5, 2022
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trialsRex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, et al.
Clinical and Molecular Hepatology|February 17, 2022
RNA interference as a novel treatment strategy for chronic hepatitis B infectionRex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
Expert Review of Gastroenterology & Hepatology|January 23, 2016
Hepatitis B: treatment choice and monitoring for response and resistanceSze-Hang Kevin Liu, Wai-Kay Seto, Ching-Lung Lai, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 7, 2024
Investigational RNA Interference Agents for Hepatitis BRex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
The Lancet. Global Health|May 13, 2022
The optimal screening strategy for chronic hepatitis B virus infection in China - Authors' replyShu Su, William Cw Wong, Jason J Ong, et al.
The American Journal of Gastroenterology|May 5, 2011
The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6Wai-Kay Seto, Yasuhito Tanaka, Kevin Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2013
Reply to Liao et alWai-Kay Seto, Danny Ka-Ho Wong, Ching-Lung Lai, et al.
Pageof 33

Showing results (41-50 of 326) with videos related to

Sort By:
Pageof 33
Lancet (London, England)|November 30, 2018
Chronic hepatitis B virus infectionWai-Kay Seto, Ying-Ru Lo, Jean-Michel Pawlotsky, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 3, 2018
An update on the toxicological considerations for protease inhibitors used for hepatitis C infectionLung-Yi Mak, Wai-Kay Seto, Ching-Lung Lai, et al.
Annals of Hematology|June 28, 2018
Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatmentHarinder Gill, Garret M K Leung, Wai-Kay Seto, et al.
Expert Opinion on Emerging Drugs|May 5, 2022
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trialsRex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, et al.
Clinical and Molecular Hepatology|February 17, 2022
RNA interference as a novel treatment strategy for chronic hepatitis B infectionRex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
Expert Review of Gastroenterology & Hepatology|January 23, 2016
Hepatitis B: treatment choice and monitoring for response and resistanceSze-Hang Kevin Liu, Wai-Kay Seto, Ching-Lung Lai, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 7, 2024
Investigational RNA Interference Agents for Hepatitis BRex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
The Lancet. Global Health|May 13, 2022
The optimal screening strategy for chronic hepatitis B virus infection in China - Authors' replyShu Su, William Cw Wong, Jason J Ong, et al.
The American Journal of Gastroenterology|May 5, 2011
The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6Wai-Kay Seto, Yasuhito Tanaka, Kevin Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2013
Reply to Liao et alWai-Kay Seto, Danny Ka-Ho Wong, Ching-Lung Lai, et al.
Pageof 33